Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Shivali Ahlawat"'
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 3, Iss 2, Pp 183-191 (2020)
Background: The impact of minimal residual disease (MRD) on overall survival (OS) is insufficiently studied in pediatric, adolescent, and young adults (AYA) with acute lymphoblastic leukemia (ALL) treated with modified MCP 841 protocol. Objectives: W
Externí odkaz:
https://doaj.org/article/e65e459d37aa4b17b2d508eaab9d28d0
Autor:
Kamalakshi G. Bhat, Shivali Ahlawat, Jayatheerth Joshi, Prashantha B, Basaviah Sridevi Hanaganahalli, Harsha Prasada Lashkari, Nutan Kamath, Moideen Faheem
Publikováno v:
Expert Review of Hematology. 13:1143-1151
Acute Lymphoblastic Leukemia (ALL) is the most common malignancy in children. With improved supportive care and a better understanding of the disease biology, it is now a curable cancer in the developed world. However, in low-income countries, the cu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c21aa13dce83a2c3e06b105735deada
https://doi.org/10.1080/17474086.2020.1813563
https://doi.org/10.1080/17474086.2020.1813563
Autor:
Rema Ganapathy, Neeraj Sidharthan, Shivali Ahlawat, Aswathy Ashok Beenakumari, Remya Sudevan, Geeta Vidyadharan, Manoj Unni, Ullas Mony, Karthika K, Syamaprasad Vinayakumar, Renjitha Bhaskaran
Publikováno v:
Blood. 138:4119-4119
Background: Children with Acute Lymphoblastic Leukemia (ALL) in Low Middle income countries(LMIC) face major challenges including treatment abandonment and poor overall survival (OS) and event-free survival (EFS).The preliminary data and results of o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a4f6b820db7eb8372d3f3ca1e5aa285
https://doi.org/10.1182/blood-2021-154307
https://doi.org/10.1182/blood-2021-154307
Autor:
Parameswaran Anoop, Venkatachalam Sandhya, Shivali Ahlawat, Kalpana Janardan, Sonal Dhande, Channappa N Patil
Publikováno v:
Indian Journal of Medical and Paediatric Oncology. 41:624-624
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f02f24a161aad57c1eb5d6cbf8d1c85
https://doi.org/10.4103/ijmpo.ijmpo_136_19
https://doi.org/10.4103/ijmpo.ijmpo_136_19
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 3, Iss 2, Pp 183-191 (2020)
Background: The impact of minimal residual disease (MRD) on overall survival (OS) is insufficiently studied in pediatric, adolescent, and young adults (AYA) with acute lymphoblastic leukemia (ALL) treated with modified MCP 841 protocol. Objectives: W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00a60640a4b6e77700e9b4c9308bfcc8
https://doi.org/10.4103/crst.crst_85_20
https://doi.org/10.4103/crst.crst_85_20